Additionally, GLP-1R agonists inhibit tau protein hyperphosphorylation, promote the release of brain-derived neurotrophic factor, and reduce neuroinflammatory responses by inhibiting microglial and astrocyte activation [55,56,57]
ISBN 92-9058-244-8
Are side effects manageable, or should you reduce
The EU5 public healthcare systems also reimburse GLP-1s, but often with prescribing restrictions such as specialist approval or use only as 3rd line treatment at the earliest, which limits penetration
Because these medications slow gastric emptying, researchers often observe: Nausea and vomiting Diarrhea or constipation Decreased appetite In early studies, Retatrutide has shown a slightly higher frequency of these side effects compared to Tirzepatide, likely due to the increased potency of the triple-receptor activation